Related Experiment Video

Updated: May 27, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Beyond castration-defining future directions in the hormonal treatment of prostate cancer

Saroj Niraula1, Kim Chi, Anthony Michael Joshua

  • 1Department of Medical Oncology, Princess Margaret Hospital, Toronto, ON, Canada.

Hormones & Cancer
|November 30, 2011
PubMed

Insights

Testosterone reduction is standard for metastatic prostate cancer, but resistance develops. New therapies target androgen pathways, offering future treatment directions for castration-resistant prostate cancer (CRPC).

Area of Science:

  • Oncology
  • Endocrinology
  • Urology

Background:

  • Testosterone's role in prostate cancer has been recognized for nearly 70 years, leading to androgen deprivation therapy (ADT) as a standard treatment.
  • Metastatic prostate cancer often progresses to castration-resistant prostate cancer (CRPC) despite initial response to ADT.
  • Mechanisms of CRPC development are complex, but many tumors remain dependent on androgens, utilizing pathways like AR amplification and intracrine synthesis.

Purpose of the Study:

  • To review the current understanding of castration resistance in prostate cancer.
  • To discuss the evolving landscape of androgen-targeted therapies.
  • To preview future clinical developments and challenges in managing advanced prostate cancer.

Main Methods:

  • Literature review of established and emerging mechanisms in prostate cancer progression.
  • Analysis of current therapeutic strategies and their limitations.
  • Discussion of novel androgen-targeted agents and their clinical implications.

Main Results:

  • Castration resistance in prostate cancer is a significant clinical challenge, driven by persistent androgen receptor signaling.
  • Emerging therapies, including abiraterone acetate and MDV3100, demonstrate efficacy by targeting androgen synthesis and action.
  • Understanding tumor biology is crucial for developing next-generation androgen-targeted agents.

Conclusions:

  • Despite initial success, ADT eventually fails, necessitating alternative treatment strategies for CRPC.
  • Next-generation androgen-targeted therapies represent a promising frontier in managing advanced prostate cancer.
  • Continued research into prostate cancer's adaptive mechanisms will guide future therapeutic innovations.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Murine Prostate Micro-dissection and Surgical Castration08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...